On the Radar: Five high-value biotech stocks

Our new On the Radar report returns with fresh insights from Simos Simeonidis, PhD, Rodman & Renshaw's senior biotech analyst, who highlights biotech stocks which he believes will be good value

Despite a mid-stage miss, Cytokinetics is taking its ALS drug toward Phase III

Earlier this year, Cytokinetics tanked as its lead prospect, a treatment for amyotrophic lateral sclerosis (ALS), missed its primary endpoint and a slew of secondary goals in a mid-stage trial. But the drug did come through on one measure of lung function, and, upon analysis of the results, the biotech believes that could be its ticket to FDA approval.

Cytokinetics Provides Development Program Update for Tirasemtiv

Robust Effects of Tirasemtiv on Slow Vital Capacity Observed in BENEFIT-ALS Support Progression to Phase III Company Believes Effects on Slow Vital Capacity Could Support Registration Path For...

Novartis clears an FDA hurdle with its pioneering psoriasis treatment

A panel of FDA advisers voted unanimously in favor of approving Novartis' new anti-inflammatory treatment, an expected positive outcome for the company as it races to be first in line among what promises to be a crowded field.

Left at the altar by AbbVie, Shire has cash, options and an M&A pedigree

While its merger with AbbVie is looking dead, Shire is likely in line for a $1.6 billion breakup fee, cash that could fund a major M&A push. And with renowned dealmakers in its executive ranks, Shire may not be lonely for long.

TesoRx licenses oral low-T drug to Aspen amid FDA crackdown

While the testosterone therapy field is under fire from government regulators, Menlo Park, CA-based TesoRx is licensing its oral-testosterone replacement therapy to a subsidiary of South African generics maker Aspen Pharmacare.

Fat-busting Neothetics files $63M IPO; Dupilumab starts PhIII; Amgen sets up an emergency Ebola team for ZMapp;

@FierceBiotech: PureTech reels in $55M to fund new biotech bets. News | Follow @FierceBiotech @JohnCFierce: Top 10 Phase III disasters of 2014. Feature | Follow @JohnCFierce @DamianFierce: ICYMI...

CUBIST PHARMACEUTICALS NAMES ROBERT J. PEREZ CHIEF EXECUTIVE OFFICER

— 10/20/2014 Michael W. Bonney to Become Non-Executive Chair of the Board of Directors Kenneth M. Bate to Become Lead Independent Director Lexington, Mass., October 20, 2014 – Cubist...

Cubist CEO Bonney hands over reins as new buyout rumors circulate

After 11 years at the helm of Cubist Pharmaceuticals, CEO Michael Bonney is stepping down and handing the reins to COO and President Robert Perez.

Interim Chief Financial Officer James Bowling to Step Down

Interim Chief Financial Officer James Bowling to Step Down DUBLIN, October 20, 2014 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPG) announces that James Bowling, Interim Chief Financial Officer...